BRCA Biomarkers
AstraZeneca Q2 Revenues Increase 31 Percent
The company reported revenues of $8.22 billion, largely driven by sales of its COVID-19 vaccine, but also due to strong performance of its oncology segment.
A recent JAMA study underscores racial disparities in genetic test access, which UPenn's Basser Center aims to address through its Black &Â BRCAÂ initiative.
Genetic Testing Challenges in Oncology: Inaccurate Patient Claims Complicate Cancer Risk Management
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
Chinese Regulators Approve Lynparza for BRCA1/2-Mutated mCRPC
China's NMPA granted conditional approval to AstraZeneca and Merck's PARP inhibitor in this setting based on the results of the PROfound trial.
ASCO Updates Guideline Recommending Adjuvant Lynparza for BRCA1/2-Mutated Early Breast Cancer
The guideline comes in the wake of the OlympiA trial results, which showed that the PARP inhibitor significantly improved invasive disease-free survival.